Table 2. Clinical trials involving bispecific antibodies in AML.

Name	Format	Phase	Endpoint	Clinical trial number	Sponsor	Study population	Status
JNJ-63709178	CD123 × CD3 DuoBody	1	Safety and efficacy	NCT02715011	Janssen Research & Development, LLC	Relapsed/refractory AML	Suspended
AMG 330	CD33 × CD3 Tandem scFv (BiTE)	1	Safety	NCT02520427	Amgen	Relapsed/refractory AML	Suspended
MGD006	CD123xCD3 DART	1	Safety	NCT02152956	MacroGenics	Relapsed/refractory AML, MDS	Recruiting

Abbreviations: AML, acute myeloid leukemia; BiTE, bispecific T-cell engager; DART, dual-affinity re-targeting; MDS, myelodysplastic syndrome.

DuoBody (Genmab, Copenhagen, Denmark) is the commercialized name of the controlled Fab-arm exchange (cFAE) platform to generate IgG1 monovalent bispecific antibodies.¹⁴⁵